Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121

The authors wish to make the following correction to this paper [1]:

Where it reads:

“In order to have a consistent, stable and defined final product for clinical human use, the Sm14 antigen was formulated with the synthetic adjuvant glucopyranosyl lipid A (GLA-SE), a clinically-approved molecule already used in a number of commercially-available human vaccines.”

It should read:

“In order to have a consistent, stable and defined final product for clinical human use, the Sm14 antigen was formulated with the synthetic adjuvant glucopyranosyl lipid A (GLA-SE), an adjuvant successfully tested in clinical trials with different human vaccine candidates.”

The authors would like to apologize for any inconvenience caused to the readers by this change.